CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+15.19%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.5B
AUM Growth
+$1.5B
(+15%)
Cap. Flow
+$39.2M
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
78.34%
Holding
38
New
–
Increased
10
Reduced
7
Closed
3
Top Buys
| 1 |
Illumina
ILMN
|
$35.2M |
| 2 |
Codexis
CDXS
|
$18.8M |
| 3 |
Standard BioTools
LAB
|
$14.1M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$6.26M |
| 5 |
Guardant Health
GH
|
$5.74M |
Top Sells
| 1 |
Revolution Medicines
RVMD
|
$13.3M |
| 2 |
Ginkgo Bioworks
DNA
|
$11.6M |
| 3 |
Pliant Therapeutics
PLRX
|
$10.8M |
| 4 |
Denali Therapeutics
DNLI
|
$9.03M |
| 5 |
Veracyte
VCYT
|
$6.52M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioLife Solutions
BLFS
$1.2B
| $218M | 14.54% | 8,707,165 | – | – |
|
|
2
Revolution Medicines
RVMD
$7.1B
| $187M | 12.44% | 4,114,283 -292,592 | -7% | -$13.3M |
|
3
GeneDx Holdings
WGS
$3.72B
| $149M | 9.92% | 3,507,164 -19,247 | -0.5% | -$817K |
|
|
4
Standard BioTools
LAB
$481M
| $138M | 9.17% | 71,254,677 +7,295,000 | +11% | +$14.1M |
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $134M | 8.94% | 1,073,500 | – | – |
|
|
6
Illumina
ILMN
$15.8B
| $97.8M | 6.52% | 750,000 +270,000 | +56% | +$35.2M |
|
7
Avidity Biosciences
RNA
$5.99B
| $95.8M | 6.38% | 2,084,841 | – | – |
|
8
Relay Therapeutics
RLAY
$619M
| $65.5M | 4.37% | 9,251,108 +802,534 | +9% | +$5.68M |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $46.8M | 3.12% | 170,000 | – | – |
|
10
Exact Sciences
EXAS
$8.98B
| $44.3M | 2.95% | 650,000 | – | – |
|
11
Intellia Therapeutics
NTLA
$1.22B
| $41.1M | 2.74% | 2,000,000 | – | – |
|
12
Structure Therapeutics
GPCR
$1.11B
| $30.7M | 2.05% | 700,000 | – | – |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $30.2M | 2.01% | 326,378 | – | – |
|
|
14
Denali Therapeutics
DNLI
$2.23B
| $28.8M | 1.92% | 990,000 -310,000 | -24% | -$9.03M |
|
|
15
Codexis
CDXS
$246M
| $24.9M | 1.66% | 8,100,000 +6,100,000 | +305% | +$18.8M |
|
|
16
Veracyte
VCYT
$2.39B
| $22.7M | 1.51% | 666,308 -191,596 | -22% | -$6.52M |
|
17
Neurogene
NGNE
$264M
| $22M | 1.47% | 524,616 | – | – |
|
|
VERV
18
DELISTED
Verve Therapeutics
VERV
| $19.3M | 1.29% | 3,995,571 +936,477 | +31% | +$4.53M |
|
19
Beam Therapeutics
BEAM
$1.66B
| $19M | 1.27% | 775,000 +100,000 | +15% | +$2.45M |
|
20
Tenaya Therapeutics
TNYA
$184M
| $13M | 0.87% | 6,732,971 | – | – |
|
21
4D Molecular Therapeutics
FDMT
$288M
| $12.4M | 0.83% | 1,150,000 +350,000 | +44% | +$3.78M |
|
|
TSVT
22
DELISTED
2seventy bio
TSVT
| $9.44M | 0.63% | 2,000,000 | – | – |
|
23
Tango Therapeutics
TNGX
$747M
| $9.15M | 0.61% | 1,188,349 | – | – |
|
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $9.14M | 0.61% | 475,000 +325,000 | +217% | +$6.26M |
|
|
25
Guardant Health
GH
$8.41B
| $8.03M | 0.54% | 350,000 +250,000 | +250% | +$5.74M |
|